The U.S. Food and Drug Administration has approved Inluriyo (imlunestrant), an oral estrogen receptor antagonist, for the ...

Estradiol is a generic prescription drug used to treat menopause-related symptoms, treat certain hormone disorders and cancers, and help prevent osteoporosis. Estradiol’s cost may depend on factors ...

Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67 ...

FDA approves Eli Lilly’s oral drug Inluriyo (imlunestrant) for ER+, HER2-, ESR1-mutated breast cancer. It cuts progression ...

BAUDETTE, Minn., Sept. 12, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for ...

The FDA has approved Eli Lilly’s imlunestrant, an oral estrogen receptor antagonist, for the treatment of adults with ...

Exposure to vaginal estradiol not linked to increased rate of recurrent ischemic stroke when adjusted for comorbidity, medications, income, education. (HealthDay News) — For women with a history of ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

Vaginal atrophy is a condition that can negatively impact the quality of life of many postmenopausal women. Local exogenous estrogen therapy can effectively alter the anatomic and pathophysiologic ...

A total of 3353 recurrent cases were identified from a cohort of 56,642 women with a first-time stroke and were matched with 3353 controls. HealthDay News — For women with a history of ischemic stroke ...